Novo Nordisk A/S
Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 15 February 2021 – On 3 February 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 3 February 2021.
Under the programme initiated 3 February 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 3 February 2021 to 3 May 2021.
Since the announcement as of 8 February 2021, the following transactions have been made:
|Accumulated, last announcement||290,000||129,758,188|
|8 February 2021||103,375||440.63||45,549,967|
|9 February 2021||110,000||439.88||48,387,166|
|10 February 2021||125,000||437.66||54,706,895|
|11 February 2021||110,000||446.07||49,067,257|
|12 February 2021||110,000||456.06||50,166,910|
|Accumulated under the programme||848,375||377,636,383|
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 28,469 B shares in the period from 8 February 2021 to 12 February 2021. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 39,761,566 B shares of DKK 0.20 as treasury shares, corresponding to 1.7% of the share capital. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 3 February 2021. As of 12 February 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 848,375 B shares at an average share price of DKK 445.13 per B share equal to a transaction value of DKK 377,636,383.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
|Anne Margrethe Hauge||+45 3079 email@example.com|
|Michael Bachner (US)||+1 609 664 firstname.lastname@example.org|
|Daniel Muusmann Bohsen||+45 3075 email@example.com|
|Valdemar Borum Svarrer||+45 3079 firstname.lastname@example.org|
|Ann Søndermølle Rendbæk||+45 3075 email@example.com|
|Mark Joseph Root||+45 3079 firstname.lastname@example.org|
|Kristoffer Due Berg (US)||+1 609 235 email@example.com|
Company announcement no. 11 / 2021
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
DBV Technologies S.A.1.3.2021 07:31:28 CET | Press release
DBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021
ORPHAZYME A/S1.3.2021 07:02:06 CET | Press release
Orphazyme appoints Christophe Bourdon as Chief Executive Officer
Idorsia Pharmaceuticals Ltd1.3.2021 07:01:56 CET | Press release
Idorsia submits NDA for clazosentan to Japanese PMDA
Hexagon Composites ASA1.3.2021 07:01:46 CET | Press release
Hexagon Agility receives additional order from major global logistics customer for CNG trucks
Santhera Pharmaceuticals Holding AG1.3.2021 07:01:36 CET | Press release
Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial
Arcadis N.V.1.3.2021 07:01:26 CET | Press release
Arcadis finds U.S., Singapore, and Japan most attractive places to build data centers
Junshi Biosciences1.3.2021 02:16:51 CET | Press release
Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom